VivoSeq
Other

EGFR Mutation

0

Pipeline Programs↗

6

Active Trials↗

9

Companies Involved↗

EGFR Mutation is an early-stage landscape with 0 programs across 9 companies. The most active players are Boehringer Ingelheim, AstraZeneca, Qilu Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalQilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalA

Avistone Biotechnology Co., Ltd.

0 programs

PreclinicalHaisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

34

clinical trials

Unknown status14 · 41%
Completed8 · 24%
Terminated6 · 18%
Recruiting4 · 12%
Not yet recruiting2 · 6%

Clinical Trials

Trial Activity

34 trials

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Recruiting·SSamsung Medical Center·Phase 2·NCT04591002·43 enrolled
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Recruiting·AAvistone Biotechnology Co., Ltd.·Phase 2·NCT07336732·40 enrolled
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
Recruiting·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06050980·220 enrolled
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
Recruiting·RRedCloud Bio·Phase 1/2·NCT05519293·76 enrolled
EGFR Mutation Targeting Molecular Probe for PET Imaging
Not yet recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT06641674·20 enrolled
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
Not yet recruiting·AAvistone Pharmaceutical（Ningbo）Co., LTD.·Phase 1/2·NCT07063329·108 enrolled
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
Completed·AstraZeneca logoAstraZeneca·N/A·NCT03137264·44 enrolled
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Completed·—·Phase 2·NCT04184921·216 enrolled
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01859026·43 enrolled
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Completed·—·Phase 2·NCT02769286·38 enrolled
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Completed·SSun Yat-sen University·Phase 2·NCT02264210·128 enrolled
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT02514174·25 enrolled
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT00949650·345 enrolled
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
Completed·YYuhan Corporation·N/A·NCT05862194·534 enrolled
Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation
Terminated·CCentre Oscar Lambret·N/A·NCT03265496·21 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)